The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Halozyme Therapeutics, Inc(NASDAQ:HALO) 
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that ...
Website: http://www.halozyme.com
Founded: 1998
Full Time Employees: 132
Sector: Healthcare
Industry: Biotechnology
Halozyme Therapeutics Days Payable Outstanding ttm (DPO)
Halozyme Therapeutics Days Receivable Outstanding ttm (DSO)
Halozyme Therapeutics Days Inventory Outstanding ttm (DIO)
Halozyme Therapeutics Op Cashflow Per Share ttm
Halozyme Therapeutics Free Cashflow Per Share ttm
Halozyme Therapeutics Cash Per Share ttm
Halozyme Therapeutics P/S ratio ttm
Halozyme Therapeutics (GAAP) P/E ratio ttm
Halozyme Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.